BCHE and Alzheimer disease: Indeed, the current pharmacological approaches for AD include three cholinesterase inhibitors (Donepezil, Galantamine, and Rivastigmine) and a N-methyl-d-aspartate (NMDA) receptor antagonist (Memantine), all of which have beneficial but only short-lived (lasting ~6 months) effects in mediating only the symptoms of AD [13].